MYBL1 and central nervous system cancer: However, gliomas typically do not express histiocytic markers and exhibit other molecular characteristics, including IDH mutations, ATRX alterations, 1p/19q co-deletions, EGFR amplification, TERT promoter mutations, H3 mutations, MYB/MYBL1 gene structural mutations, and FGFR1 mutations, etc (21).